264 related articles for article (PubMed ID: 28544654)
1. Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome.
Bogefors C; Isaksson S; Bobjer J; Kitlinski M; Leijonhufvud I; Link K; Giwercman A
Andrology; 2017 Jul; 5(4):711-717. PubMed ID: 28544654
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction.
García-Cruz E; Leibar-Tamayo A; Romero J; Piqueras M; Luque P; Cardeñosa O; Alcaraz A
J Sex Med; 2013 Oct; 10(10):2529-38. PubMed ID: 23898860
[TBL] [Abstract][Full Text] [Related]
3. Low-grade inflammation in survivors of childhood cancer and testicular cancer and its association with hypogonadism and metabolic risk factors.
Ekedahl H; Isaksson S; Ståhl O; Bogefors K; Romerius P; Eberhard J; Giwercman A
BMC Cancer; 2022 Feb; 22(1):157. PubMed ID: 35135482
[TBL] [Abstract][Full Text] [Related]
4. Reproductive hormones and metabolic syndrome in 24 testicular cancer survivors and their biological brothers.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Oturai PS; Mortensen J; Hojman P; Helge JW; Daugaard G
Andrology; 2017 Jul; 5(4):718-724. PubMed ID: 28598554
[TBL] [Abstract][Full Text] [Related]
5. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Oturai PS; Mortensen J; Hojman P; Helge JW; Daugaard G
Eur J Cancer; 2017 Oct; 84():9-17. PubMed ID: 28772110
[TBL] [Abstract][Full Text] [Related]
6. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer.
Nord C; Bjøro T; Ellingsen D; Mykletun A; Dahl O; Klepp O; Bremnes RM; Wist E; Fosså SD
Eur Urol; 2003 Sep; 44(3):322-8. PubMed ID: 12932930
[TBL] [Abstract][Full Text] [Related]
7. Follicle-Stimulating Hormone, Its Association with Cardiometabolic Risk Factors, and 10-Year Risk of Cardiovascular Disease in Postmenopausal Women.
Wang N; Shao H; Chen Y; Xia F; Chi C; Li Q; Han B; Teng Y; Lu Y
J Am Heart Assoc; 2017 Aug; 6(9):. PubMed ID: 28855169
[TBL] [Abstract][Full Text] [Related]
8. Hypogonadism risk in men treated for childhood cancer.
Romerius P; Ståhl O; Moëll C; Relander T; Cavallin-Ståhl E; Wiebe T; Giwercman YL; Giwercman A
J Clin Endocrinol Metab; 2009 Nov; 94(11):4180-6. PubMed ID: 19789207
[TBL] [Abstract][Full Text] [Related]
9. Hypogonadism and androgen deficiency symptoms in testicular cancer survivors.
Lackner JE; Märk I; Schatzl G; Marberger M; Kratzik C
Urology; 2007 Apr; 69(4):754-8. PubMed ID: 17445664
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.
Willemse PM; Burggraaf J; Hamdy NA; Weijl NI; Vossen CY; van Wulften L; van Steijn-van Tol AQ; Rosendaal FR; Osanto S
Br J Cancer; 2013 Jul; 109(1):60-7. PubMed ID: 23660945
[TBL] [Abstract][Full Text] [Related]
11. Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial.
Adams SC; DeLorey DS; Davenport MH; Stickland MK; Fairey AS; North S; Szczotka A; Courneya KS
Cancer; 2017 Oct; 123(20):4057-4065. PubMed ID: 28708930
[TBL] [Abstract][Full Text] [Related]
12. Re: Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.
Seftel A
J Urol; 2013 Nov; 190(5):1768. PubMed ID: 24120785
[No Abstract] [Full Text] [Related]
13. High risk of hypogonadism in young male cancer survivors.
Isaksson S; Bogefors K; Ståhl O; Eberhard J; Giwercman YL; Leijonhufvud I; Link K; Øra I; Romerius P; Bobjer J; Giwercman A
Clin Endocrinol (Oxf); 2018 Mar; 88(3):432-441. PubMed ID: 29245176
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy.
Gomes AR; Souteiro P; Silva CG; Sousa-Pinto B; Almeida F; Sarmento A; Carvalho D; Freitas P
BMC Infect Dis; 2016 Nov; 16(1):628. PubMed ID: 27809804
[TBL] [Abstract][Full Text] [Related]
15. Does long-term androgen deficiency lead to metabolic syndrome in middle-aged rats?
Borbélyová V; Domonkos E; Bábíčková J; Tóthová Ľ; Kačmárová M; Uličná O; Ostatníková D; Hodosy J; Celec P
Exp Gerontol; 2017 Nov; 98():38-46. PubMed ID: 28807822
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of hypogonadism and associated impaired metabolic and bone mineral status in subfertile men.
Bobjer J; Bogefors K; Isaksson S; Leijonhufvud I; Åkesson K; Giwercman YL; Giwercman A
Clin Endocrinol (Oxf); 2016 Aug; 85(2):189-95. PubMed ID: 26857217
[TBL] [Abstract][Full Text] [Related]
17. Late-onset hypogonadism: metabolic impact.
Grossmann M; Ng Tang Fui M; Cheung AS
Andrology; 2020 Nov; 8(6):1519-1529. PubMed ID: 31502758
[TBL] [Abstract][Full Text] [Related]
18. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
[TBL] [Abstract][Full Text] [Related]
19. Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Boer H; Westerink NL; Altena R; Nuver J; Dijck-Brouwer DAJ; van Faassen M; Klont F; Kema IP; Lefrandt JD; Zwart N; Boezen HM; Smit AJ; Meijer C; Gietema JA
Eur J Cancer; 2016 Feb; 54():104-111. PubMed ID: 26751392
[TBL] [Abstract][Full Text] [Related]
20. Hypogonadism and fertility issues following primary treatment for testicular cancer.
Oldenburg J
Urol Oncol; 2015 Sep; 33(9):407-12. PubMed ID: 25736189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
